Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,307.20 -80.41 -0.52%
S&P 500 1,655.35 -13.81 -0.83%
Nasdaq 3,463.30 -38.82 -1.11%
Ticker Volume Price Price Delta
STOXX 50 2,835.01 +13.36 0.47%
FTSE 100 6,840.27 +36.40 0.53%
DAX 8,530.89 +58.69 0.69%
Ticker Volume Price Price Delta
Nikkei 14,484.00 -1,143.28 -7.32%
Hang Seng 22,648.10 -612.94 -2.64%
S&P/ASX 200 5,062.40 -102.97 -1.99%
  • Fund Type: Closed-End Fund
  • Objective: Sector Fund-Health & Biotech
  • Asset Class: Equity
  • Geographic Focus: Global

BB Biotech AG

+ Add to Watchlist

BIOEE:SW

123.5000 CHF 0.00000.00%

As of 11:09:43 ET on 05/22/2013.

Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Snapshot for BB Biotech AG (BIOEE)

Open: - High - Low: - Primary Exchange: SIX Swiss Ex
Volume: 2,500 52-Week Range: 74.5000 - 123.5000 Beta vs NBI: 0.7635

ETF Chart for BIOEE

No chart data available.
  • BIOEE:SW 123.5000
  • 1D
  • 1M
  • 1Y
123.5000
Interactive BIOEE Chart

Previous Close

Fund Profile & Information for BIOEE

BB Biotech AG is an investment company. The Company invests in biotech companies that operate in areas that include oncology, cardiovascular diseases, infectious diseases and autoimmune diseases.

Inception Date: 2006-11-06 Telephone: Tel: +41 44 267 67 00
Managers: DANIEL KOLLER
Web Site: www.bbbiotech.ch/en/bb-biotech/

Fundamentals for BIOEE

NAV (on 2007-05-16) 13.0500
Assets (M) (on 2002-12-31) 1,579.0000
Shares out (M) 0.00
Market Cap (M) 0.00
% Premium -
Average 52-Week % Premium -
Fund Leveraged N

Dividends for BIOEE

No dividends reported

Performance for BIOEE

1-Month +10.76% 1-Year +56.93%
3-Month +25.76% 3-Year +26.45%
Year To Date +39.23% 5-Year +8.27%
Expense Ratio -

Top Fund Holdings for BIOEE

Filing Date: 03/31/2012
Name Position Value % of Total
Celgene Corp 2,600,000 181,900,000 16.293%
Actelion Ltd 4,226,115 139,500,000 12.496%
Vertex Pharmaceuticals Inc 2,822,684 104,500,000 9.360%
Gilead Sciences Inc 4,220,000 93,000,000 8.330%
Incyte Corp Ltd 4,980,000 86,700,000 7.766%
Novo Nordisk A/S 591,056 73,900,000 6.619%
Isis Pharmaceuticals Inc 7,233,800 57,200,000 5.124%
Halozyme Therapeutics Inc 4,800,000 55,300,000 4.953%
Amylin Pharmaceuticals LLC 2,323,391 52,300,000 4.685%
ImmunoGen Inc 3,666,300 47,600,000 4.264%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil